niacinamide has been researched along with Exanthem in 14 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)." | 9.20 | Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 8.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 7.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| "Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)." | 7.76 | Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010) |
| " The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)." | 6.84 | Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017) |
| " However, there is lack of data in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC)." | 5.20 | Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015) |
| " Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis." | 4.84 | Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. ( Bonomi, L; Imarisio, I; Paglino, C; Porta, C, 2007) |
| "We report a 63-year-old Caucasian male who developed multiple cutaneous eruptive keratoacanthomas after starting sorafenib 400 mg twice daily." | 4.02 | Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report. ( Abbas, MN; Kichenadasse, G; Tan, WS, 2021) |
| " Sorafenib concentrations were significantly greater in patients with grade ≥2 HFSR and hypertension than in those not experiencing the adverse events (p = 0." | 3.80 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. ( Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014) |
| "Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC)." | 3.76 | Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. ( Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B, 2010) |
| " The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)." | 2.84 | Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017) |
| " In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily." | 2.75 | A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. ( Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L, 2010) |
| "Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs." | 2.48 | Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. ( Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012) |
| "Sorafenib is a novel oral bis-aryl urea compound originally developed as an inhibitor of RAF kinase for its anti-proliferative property." | 2.46 | Toxicity of sorafenib: clinical and molecular aspects. ( Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B, 2010) |
| "Sorafenib was well tolerated at the RDP, and induced sustained disease stabilization, particularly in patients with skin toxicity/diarrhoea." | 2.43 | Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? ( Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D, 2006) |
| " The dosage was temporarily reduced in only two patients, and oral steroids were added in four." | 1.43 | Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic. ( Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM, 2016) |
| "A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed." | 1.38 | Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. ( Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, MN | 1 |
| Tan, WS | 1 |
| Kichenadasse, G | 1 |
| Fukudo, M | 1 |
| Ito, T | 1 |
| Mizuno, T | 1 |
| Shinsako, K | 1 |
| Hatano, E | 1 |
| Uemoto, S | 1 |
| Kamba, T | 1 |
| Yamasaki, T | 1 |
| Ogawa, O | 1 |
| Seno, H | 1 |
| Chiba, T | 2 |
| Matsubara, K | 1 |
| Ogasawara, S | 1 |
| Ooka, Y | 1 |
| Suzuki, E | 1 |
| Kanogawa, N | 1 |
| Saito, T | 1 |
| Motoyama, T | 1 |
| Tawada, A | 1 |
| Kanai, F | 1 |
| Yokosuka, O | 1 |
| Ollech, A | 1 |
| Stemmer, SM | 1 |
| Merims, S | 1 |
| Lotem, M | 1 |
| Popovtzer, A | 1 |
| Hendler, D | 1 |
| Hodak, E | 1 |
| Didkovsky, E | 1 |
| Amitay-Laish, I | 1 |
| Luo, X | 1 |
| Jia, W | 1 |
| Huang, Z | 1 |
| Li, X | 1 |
| Xing, B | 1 |
| Jiang, X | 1 |
| Li, J | 1 |
| Si, A | 1 |
| Yang, T | 1 |
| Gao, C | 1 |
| Lau, WY | 1 |
| Shen, F | 1 |
| Gomberg-Maitland, M | 1 |
| Maitland, ML | 1 |
| Barst, RJ | 1 |
| Sugeng, L | 1 |
| Coslet, S | 1 |
| Perrino, TJ | 1 |
| Bond, L | 1 |
| Lacouture, ME | 1 |
| Archer, SL | 1 |
| Ratain, MJ | 1 |
| Vincenzi, B | 1 |
| Santini, D | 1 |
| Russo, A | 1 |
| Addeo, R | 1 |
| Giuliani, F | 1 |
| Montella, L | 1 |
| Rizzo, S | 1 |
| Venditti, O | 1 |
| Frezza, AM | 1 |
| Caraglia, M | 1 |
| Colucci, G | 1 |
| Del Prete, S | 1 |
| Tonini, G | 1 |
| Blanchet, B | 1 |
| Billemont, B | 1 |
| Barete, S | 1 |
| Garrigue, H | 1 |
| Cabanes, L | 1 |
| Coriat, R | 1 |
| Francès, C | 1 |
| Knebelmann, B | 1 |
| Goldwasser, F | 1 |
| Bracarda, S | 1 |
| Ruggeri, EM | 1 |
| Monti, M | 1 |
| Merlano, M | 1 |
| D'Angelo, A | 1 |
| Ferraù, F | 1 |
| Cortesi, E | 1 |
| Santoro, A | 1 |
| Poprach, A | 1 |
| Pavlik, T | 1 |
| Melichar, B | 1 |
| Puzanov, I | 1 |
| Dusek, L | 1 |
| Bortlicek, Z | 1 |
| Vyzula, R | 1 |
| Abrahamova, J | 1 |
| Buchler, T | 1 |
| Tsuchiya, N | 1 |
| Narita, S | 1 |
| Inoue, T | 1 |
| Hasunuma, N | 1 |
| Numakura, K | 1 |
| Horikawa, Y | 1 |
| Satoh, S | 1 |
| Notoya, T | 1 |
| Fujishima, N | 1 |
| Hatakeyama, S | 1 |
| Ohyama, C | 1 |
| Habuchi, T | 1 |
| Hilger, RA | 1 |
| Kredtke, S | 1 |
| Scheulen, ME | 1 |
| Seeber, S | 2 |
| Strumberg, D | 2 |
| Awada, A | 1 |
| Hirte, H | 1 |
| Clark, JW | 1 |
| Piccart, P | 1 |
| Hofstra, E | 1 |
| Voliotis, D | 1 |
| Christensen, O | 1 |
| Brueckner, A | 1 |
| Schwartz, B | 1 |
| Porta, C | 1 |
| Paglino, C | 1 |
| Imarisio, I | 1 |
| Bonomi, L | 1 |
4 reviews available for niacinamide and Exanthem
| Article | Year |
|---|---|
Toxicity of sorafenib: clinical and molecular aspects.
Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidn | 2010 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease M | 2012 |
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Tr | 2006 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Hum | 2007 |
5 trials available for niacinamide and Exanthem
| Article | Year |
|---|---|
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue | 2015 |
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administrati | 2017 |
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Femal | 2010 |
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Bindin | 2013 |
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Human | 2004 |
5 other studies available for niacinamide and Exanthem
| Article | Year |
|---|---|
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Ag | 2021 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carc | 2014 |
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; | 2016 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; | 2010 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; | 2012 |